PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
The growth of cell line development
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
The promise of mRNA therapeutics in producing the first regenerative treatment for SUI
Dr Roger Dmochowski, Professor of Urology and Associate Surgeon in Chief for Vanderbilt University Medical Center, discusses the promise of potential new regenerative for Stress Urinary Incontinence.
Developing modern vaccines against an underrecognised foe
Messenger RNA (mRNA) may be the ‘skeleton key’ that unlocks the door to fight latent viral infections that have plagued researchers for generations. Dr Sandeep Basnet, Director, Clinical Development at Moderna Therapeutics explores modern vaccine development and why mRNA is taking centre stage.
Novel systems for realising the promise of DNA vaccines and enabling the next generation of genetic medicines
Dr John Lewis, CEO of Entos Pharmaceuticals, outlines how an innovative proteolipid platform could enable a new class of DNA-based vaccines in this article.
Are scientists closing in on vaccines for Alzheimer’s and Parkinson’s?
Protecting against conditions that appear in older generations is increasingly becoming a focus of the medical industry. In this article, Dr Andrea Pfeifer, CEO and Director of AC Immune, discusses the current landscape of vaccine development for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Drug Target Review Antibodies ebook 2022
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
Drug Target Review Immuno-oncology ebook 2022
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
Novel modalities of recently approved drugs
Dr Sheraz Gul reviews the drug approvals from 2021 and highlights the novel modalities of molecules that target KRAS and HIF-2α, which have historically been considered as undruggable.
Uniting industry and academia for phenotypic drug discovery
A collaboration between Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) has been established to source cellular functional assays from the global academic community, with the goal of developing novel screens and identifying targets and therapeutic candidates for unmet medical needs. Here, Dr Denise Barrault, Director of…
Driving precision neurology forwards with iPSCs and new assays
Precision medicine in neurology is limited by a dearth of clinically relevant models. However, here Dr Evangelos Kiskinis, Assistant Professor at Northwestern University Feinberg School of Medicine, discusses how new technologies such as bioelectronic assays enable real-time, long-term analysis of neurological diseases in a dish, offering a pathway towards identifying…
Drug Target Review Assays ebook 2022
In this ebook, you can find articles on the development of novel assays and technology - download now for free!
Drug Target Review Vaccine Development ebook 2022
In this ebook, find articles on vaccination strategies for neurodegenerative diseases and the benefits of mRNA vaccine platforms against latent viruses.
Enhancing confocal microscopy with AI
Improving processes in the lab can enable researchers to spend their time on other tasks and increase the accuracy of their findings, including when imaging. In this Q&A, Dr Hari Shroff from the US National Institutes of Health (NIH) discusses his recent study, published in Nature where confocal microscopy was…
An equal seat at the table for AI in pharmaceutical discovery
This article explores the current state of artificial intelligence (AI) in drug discovery and development, discussing the obstacles holding back wider adoption. Dr Mark Eller, Senior Vice President of Research and Development at Aria Pharmaceuticals, makes the case that to succeed, AI must be integrated as a partner alongside core…
Drug Target Review – Issue 1 2022
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
